tbuckley/cabot-search huggingface dataset:
Acupuncture analgesia.
Authors: F S Rickards
Journal: BMJ (1977)

bosis did not improve as formerly and residual pain, though not troublesome, still remained in the following June.The above case seems to be the first in which ancrod has been given in repeated courses.Antibody formation, investigated by radioimmunoassay after the fifth course, was negligible.Hydrocortisone may have played some part in this because it is known that corticosteroids can suppress antibody forma- tion under some conditions.'iIn this patient the most useful benefit appears to be in reducing the incidence of, thromboembolism after the ancrod therapy.Our evidence for this is based on the number of thromboembolic incidents pre-and post-ancrod administration.Though this point has not been established with certainty, it could, if confirmed, prove a valuable addition to our anticoagulant therapy.
Vocal Genetics
Authors: Bridget M. Kuehn
Journal: JAMA (2010)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Index of Subjects, Volume 15
Journal: JNCI Journal of the National Cancer Institute (1955)

Journal Article Index of Subjects, Volume 15 Get access JNCI: Journal of the National Cancer Institute, Volume 15, Issue 6, June 1955, Pages XVII–XXVII, https://doi.org/10.1093/jnci/15.6.XVII Published: 01 June 1955
Phase II Trial to study the efficacy and toxicity of combined docetaxel (D), carboplatin (C), +/− trastuzumab (T) administered weekly in patients with HER-2/neu +/− metastatic breast cancer (MBC)
Authors: S. E. Waintraub
Journal: Journal of Clinical Oncology (2004)

803 Background: D as a single agent is associated with the highest reported response rates and response duration in metastatic breast cancer. Though D is commonly delivered as an every 3 week dose, newer studies have shown that weekly delivery of the drug is safe and associated with an equal or greater response rate and less toxicity. C is an active agent in metastatic breast cancer and has shown synergy with the taxanes. T has significant activity in HER2 neu + MBC and is synergistic with the platinums and the taxanes. Synergy between the taxanes, carboplatin and trastuzumab has been established. The use of D+C on an every 3 week basis with weekly T in MBC has been shown to have very high response rates. However, it is possible that weekly administration of a combination of these drugs results in higher response rates and less toxicity than every 3 week regimens. Methods: We are studying the safety and efficacy of weekly D at 25mg/m2 iv and weekly C at AUC 2 iv, given days 1, 8, 15 every 28 days, with weekly T given iv only for FISH + HER2/neu patients with a loading dose of 4mg/kg on week 1 and then 2mg/kg/week in previously untreated women with MBC. All patients receive 10mg dexamethasone pre-medication intravenously one hour before D administration. The objectives of the study are to evaluate response rates, safety, and progression free survival. All patients will be restaged every 8 weeks for response assessment. Results: We have to date enrolled 12 pts, 10 of whom remain evaluable. Data on responses rates, toxicity, and safety will be made available. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Bristol-Myers Squibb Bristol-Myers Squibb Bristol-Myers Squibb Bristol-Myers Squibb Oncology
Antitumor compounds from tunicates
Authors: Kenneth L. Rinehart
Journal: Medicinal Research Reviews (2000)

Of the six marine-derived compounds that have reached clinical trials as antitumor agents three—didemnin B, Aplidine, and ecteinascidin 743—are derived from tunicates. Di-demnin B (DB), a cyclic depsipeptide from the compound tunicate Trididemnum solidum, was the first marine-derived compound to enter Phases I and II clinical trials. The Phase II studies, sponsored by the U. S. National Cancer Institute, indicated complete or partial remissions with non-Hodgkins lymphoma, but cardiotoxicity caused didemnin B to be dropped from further study. The closely related dehydrodidemnin B (DDB, Aplidine) was isolated in 1988 from a second colonial tunicate, Aplidium albicans, and spectroscopic studies assigned a structural formula in which a pyruvyl group in DDB replaced the lactyl group in DB and syntheses of DDB have been achieved. Aplidine is more active than DB and lacks DB's cardiotoxicity. It was introduced by PharmaMar into Phase I clinical trials in January 1999. The second family of tunicate-derived antitumor agents are the ecteinascidins (ETs), from the mangrove tunicate Ecteinascidia turbinata. The antitumor extracts of E. turbinata were first described in 1969, but the small amount of ETs in E. turbinata prevented their isolation for over a decade. The structures of ETs have been assigned mainly by spectroscopy. Phase II clinical trials with ET 743 are underway. Future supplies of ET's should be available from aquaculture or synthesis. © 2000 John Wiley & Sons, Inc. Med Res Rev, 20, No. 1, 1–27, 2000
Lærebog I: Menneskets Arvelighedsforhold udarbejdet til Brug for Læger og medicinsk Studerende.
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Update: Mortality Attributable to HIV Infection Among Persons Aged 25-44 Years— United States, 1991 and 1992
Journal: JAMA (1993)

During the 1980s, human immunodeficiency virus (HIV) infection emerged as a leading cause of death in the United States (1). In 1992, HIV infection became the number one cause of death among men aged 25-44 years. This report updates national trends in deaths caused by HIV infection for 1991 and 1992.
"STRONGYLOIDES INTESTINALIS INFESTATION"
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Early Medicine and Magic
Journal: JAMA (1988)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Wording Error in: Scientists Probe Herpes in Neonates, <i>C difficile</i> Acquisition in Children
Authors: Allison Agwu, Susie Jang, P Korthuis, Maria Rosario, G Araneta, Kelly Gebo, Araneta Korthuis, Jang Agwu, Richard Rutstein, Jeffrey Jacobson, Sara Allen, Richard Moore, Robert Beil, Carolyn Chu, Patrick Nemechek, Gary Sinclair, Laura Armas-Kolostroubis, Stephen Spector, W Mathews, Jonathan Cohn, Jeanne Keruly, Cindy Voss, Bonnie Cameron
Journal: JAMA (2011)

20 to 24 years, respectively. 3The reasons for the observed rates, particularly among BIY, may be multifactorial.Behaviorally infected youth may have other characteristics that were not studied (eg, pregnancy desire) that increased pregnancy risk.Compared with nationally observed data in youth, there were higher rates of premature births (34.4% vs 21.5%) and spontaneous abortions (13.5% vs 8.9%). 4,5Vertically infected youth were more likely than BIY to electively terminate pregnancy.Our findings are not generalizable to all clinics caring for HIV-infected youth.The study is limited by its retrospective nature, small numbers, and limited follow-up time for BIY.Early risk reduction to prevent unplanned pregnancies among HIV-infected youth is critical.Studies to understand differences in reproductive attitudes and decision making between VIY and BIY are vital to optimizing counseling and medical care for this population.
Cytokine inhibition of the hepatitis B virus core promoter
Authors: R ROMERO
Journal: Hepatology (1996)

Hepatitis B virus (HBV) DNA contains consensus elements for transactivating proteins whose binding activity in other systems is regulated by inflammatory cytokines. Because HBV replicates within an environment of provoked inflammation, we speculated that the HBV core/pregenomic promoter may be regulated by cytokines produced in response to infection. To evaluate this hypothesis, the HBV core/pregenomic (C/P) promoter and associated cis-acting elements were placed upstream of a luciferase-encoding plasmid. This reporter construct was transfected into cytokine-sensitive hepatoma cells permissive for HBV replication, which were exposed to stimulated mononuclear cell-conditioned medium or human recombinant cytokines. Conditioned medium reduced luciferase expression by 80%. Tumor necrosis factor α (TNF-α), interferon gamma (IFN-γ), and interferon alfa (IFN-α) each reduced luciferase activity by 40%. Combinations of TNF-α and interferons mimicked the extent of conditioned medium inhibition. Non-specific effects from diminished cellular viability or growth were not responsible for decreased luciferase activity. Retention of HBV DNA 330 basepairs upstream of the C/P transcription start site was required to maintain the TNF-α effect. A 60% reduction in HBV replicative forms within intracellular core particles was demonstrated with TNF-α treatment of Hep G2 cells stably transfected with HBV DNA. The inhibitory action of these cytokines implicates a noncytolytic mechanism by which antigen-nonspecific immune responses in part regulate HBV replication in infected hepatocytes. This function may be beneficial in accelerating viral clearance, but in alternative circumstances could contribute to viral persistence by attenuating immunogen recognition.
Some factors influencing the development of a voluntary PKU screening program. Possible implication for other screening procedures for newborns
Authors: V. A. Holm
Journal: JAMA (1970)

Mandatory legislation for phenylketonuria (PKU) screening has recently created considerable controversy. This report analyzes three years' experience with a voluntary program in the state of Washington. Sixty-nine percent of newborns were screened in 1967, the last year of the survey reported. The major factor influencing development of screening practice seemed to be physician interrelationships, strongest in the most populous communities, which either favored or hindered the adoption of a screening program. Other medicosociological factors considered had less or no influence. Further observations made that might be considered when planning future mass screening programs were (1) sparsely populated areas and small hospitals need support; (2) the type of testing policy adopted by a hospital staff determines the effectiveness of its program; and (3) screening programs need periodic surveillance to continue to be effective.
Annual Reports of the Supervising Surgeon-General of the Marine-Hospital Service of the United States. For the Years 1900 and 1901.
Journal: JAMA (1903)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Drug-Drug Interactions in Patients Treated for Cancer: a Prospective Study on Clinical Interventions
Authors: R.W. van Leeuwen, F.G.A. Jansman, P.M.L.A. van den Bemt, F. De Man, F. Piran, I. Vincenten, A. Jager, A.W. Rijneveld, R.H.J. Mathijssen, T. van Gelder
Journal: Annals of Oncology (2014)
Are written responses to some referrals to a general haematology clinic acceptable?
Journal: BMJ (2004)

Data were voluntarily provided by members of the Society of Cardiothoracic Surgeons of Great Britain and Ireland.Tom Treasure is responsible to the society for the collection and collation of these data and has a mandate from the society's annual general meeting of its members to disseminate information based on the data.Contributors: AS, TT, and JvdM were responsible for study concept and design.TT and AS were responsible for acquisition of the data and administrative, technical, or material support.AS and JL analysed the data and provided statistical expertise.
ABORTION AND THE LAW
Journal: JAMA (1967)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 774: Regulation of autophagy and epigenetic modulator micro RNA by transient receptor potential melastatin 7 (TRPM7) channel in glioma
Authors: Mingli Liu
Journal: Cancer Research (2019)

Abstract High grade malignant gliomas are devastating, uniformly fatal cancers for which no effective therapies currently exist. Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor. We have reported that TRPM7 channels, a subfamily member of the transient receptor potential (TRP), regulate glioma stem cell (GSC) growth/proliferation through STAT3 and Notch signaling pathways. Autophagy is a catabolic process that occurs during both physiological and pathological process which has been reported to have dual roles, functioning either as a tumor-suppressor or tumor-promoter in cancer, including glioma. In addition, because of the limited success of the traditional treatment in prolonging the overall survival in GBM patients, epigenetics and epigenetic modulators have been attracting an increasing amount of attention for their influence in many aspects of cancer. microRNAs (miRNA), which can be considered as epigenetic effectors, reversibly regulate transcription through binding to complementary sequences of mRNA and silencing its translation into proteins. Therefore, we first determined the role of autophagy process in regulating glioma by TRPM7 using real time RT2 Profile PCR arrays (SABioscience, PAHS-084Z). We found that ATG16L1, ATG9A, CDKN1B, CLN3, CXCR4, and RGS19 were upregulated in response to TRPM7 silencing with the fold change greater than 1.6 using the A172 cell line of human glioma. The gene changes were further validated in other three glioma cell lines U87MG, U373MG and SNB19, which demonstrated different glioma tumorigenicity. miroRNA microarray analysis were then were performed upon TRPM7 silencing in A172 cells (www.LCsciences.com). In-depth data analysis from miRNA microarray data showed a list of 16 downregulated and 10 upregulated miRNA whose transcripts are statistically significant with fold change greater than 2 by TRPM7 knock-down. Among these, the micro RNA of hsa-miR-26b-5p, has-miR4530, and has-miR-28-5p have shown to exert crucial influence on tumor growth and migration by modulating AKT, ERK and IGF-1 signaling pathways. Stem-loop RT-qPCR were then used to detect and quantify miRNAs identified in miRNA microarray data from U87MG, U373MG and SNB19 cell lines. Our data indicate that autophagy effects serve as tumor suppressors in gliomagenesis and are reversely regulated by TRPM7; while hsa-miR-26b-5p, has-miR4530, and has-miR-28-5p are regulated by TRPM7 and participate in glioma progression. Citation Format: Mingli Liu. Regulation of autophagy and epigenetic modulator micro RNA by transient receptor potential melastatin 7 (TRPM7) channel in glioma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 774.
SYNERGIC TOXINS OF DIPHTHERIA GRAVIS
Journal: JAMA (1942)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
HUNGARY
Journal: JAMA (1962)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal